.png){kind=icon}
返回
Advancing therapy for osteosarcoma
.png){kind=icon}
PRE
AI
DOI：10.1038/s41571-021-00519-8.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Despite being the most common primary bone cancer in children and young adults, osteosarcoma is a rare cancer, a fact that has complicated efforts to improve patient outcomes. Moreover, the molecular biology of disease is highly heterogeneous and most of the recurrent genetic alterations occur in tumour-suppressor genes that are challenging therapeutic targets. Herein, Gill and Gorlick discuss the new biological discoveries, technologies, and therapeutic agents and approaches that, through collaborative efforts, are poised to generate advances in the treatment of osteosarcoma after more than four decades of stagnation. Improving the survival of patients with osteosarcoma has long proved challenging, although the treatment of this disease is on the precipice of advancement. The increasing feasibility of molecular profiling together with the creation of both robust model systems and large, well-annotated tissue banks has led to an increased understanding of osteosarcoma biology. The historical invariability of survival outcomes and the limited number of agents known to be active in the treatment of this disease facilitate clinical trials designed to identify efficacious novel therapies using small cohorts of patients. In addition, trial designs will increasingly consider the genetic background of the tumour through biomarker-based patient selection, thereby enriching for clinical activity. Indeed, osteosarcoma cells are known to express a number of surface proteins that might be of therapeutic relevance, including B7-H3, GD2 and HER2, which can be targeted using antibody-drug conjugates and/or adoptive cell therapies. In addition, immune-checkpoint inhibition might augment the latter approach by helping to overcome the immunosuppressive tumour microenvironment. In this Review, we provide a brief overview of current osteosarcoma therapy before focusing on the biological insights from the molecular profiling and preclinical modelling studies that have opened new therapeutic opportunities in this disease.
Keyword:
HIGH-GRADE OSTEOSARCOMA
CHILDRENS ONCOLOGY GROUP
ANTIBODY-DRUG CONJUGATE
GROWTH-FACTOR RECEPTOR
PHASE-II TRIAL
GLEMBATUMUMAB VEDOTIN CDX-011
PRECLINICAL TESTING PROGRAM
HIGH-DOSE METHOTREXATE
RECURRENT OSTEOSARCOMA
NEOADJUVANT CHEMOTHERAPY
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
82.2
论文数:
2.4K
被引数:
3.3W
机构
引用论文
Cerebellar functional abnormalities in early stage drug-naïve and medicated Parkinson’s disease
PREAI
分享收藏
Development of a novel immune-related genes prognostic signature for osteosarcoma骨肉瘤新的免疫相关基因预后标记的开发.png)
SCIENTIFIC REPORTS
OAAI
SCIENTIFIC REPORTSIF3.9
OAAI分享收藏Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing使用全基因组测序对2,658种人类癌症中的色素病进行综合分析NATURE GENETICSOAAI
NATURE GENETICSIF31.8
OAAI分享收藏In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)PE38 against breast cancer, osteosarcoma, and neuroblastomaCANCER RESEARCHOAAI
CANCER RESEARCHIF16.6
OAAI分享收藏Addition of Muramyl Tripeptide to Chemotherapy for Patients With Newly Diagnosed Metastatic OsteosarcomaCANCEROAAI
CANCERIF5.1
OAAI分享收藏
查看更多内容